Octreotide LAR as Maintenance Treatment for Patients With NEC
NCT02409849
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
92
Enrollment
OTHER
Sponsor class
Conditions
Gastro-entero-pancreatic Carcinoma
Esophageal Neuroendocrine Carcinoma
Interventions
DRUG:
Octreotide lar
Sponsor
Peking University